Kidney stones increase after menopause, suggesting a role for estrogen deficiency. ArKO mice have hypercalciuria and lower levels of calcium transport proteins, whereas levels of the klotho protein are elevated. Thus, estrogen deficiency is sufficient to cause altered renal calcium handling.
INTRODUCTION
T HE INCIDENCE OF kidney stones in women is lower than in men throughout adult life. Premenopausal women have one half the prevalence of calcium stone disease than men of comparable age. (1, 2) However, this sex difference disappears rapidly after the onset of menopause. (3) (4) (5) By 55-60 yr of age, the prevalence of calcium stone disease is equal in men and women and remains equal henceforth. (5) Several studies have provided evidence that urinary calcium excretion increases at menopause, (6) (7) (8) thereby increasing the risk for calcium-containing stones. However, additional changes in urinary composition (e.g., hypocitraturia, hyperoxaluria, hyperuricosuria) could also contribute to an increased risk for renal stones. We recently undertook a retrospective analysis of the database from our large kidney stone patient registry and identified a major role for the increased urinary calcium excretion in postmenopausal women with kidney stones. (6) Nordin and Polley (7) compared urinary calcium excretion in matched pairs of normal pre-and postmenopausal women who had not received hormone replacement therapy. Urine calcium/creatinine was significantly greater in the postmenopausal women. This rise in calcium excretion at the menopause could not be accounted for by the associated rise in plasma calcium or its fractions because it remained significant even when pre-and postmenopausal women were matched for total, ultrafilterable, ionized, or complexed calcium. The authors suggested that estrogens promote tubular reabsorption of calcium, an observation that was subsequently confirmed in a second study by the same investigators. (8) McKane et al. (9) also examined the effect of estrogen replacement therapy (ERT) on renal tubular calcium reabsorption before and after 6 mo of therapy in early postmenopausal women (median age, 51 yr). Their study is significant in that they directly measured serum ultrafilterable calcium and tubular reabsorption of calcium before and during PTH clamp. Before PTH administration, ERT had no effect on serum ultrafilterable calcium. ERT increased the tubular reabsorption of calcium, an effect ascribed to a commensurate increase in PTH and consistent with an effect of ERT in reducing bone resorption. However, after PTH clamp, the tubular reabsorption of calcium was greater after ERT than at baseline, suggesting a direct effect of ERT in promoting increased tubular reabsorption of calcium independent of PTH's action. Taken together, these observations are consistent with the hypothesis that impaired tubular reabsorption of calcium and renal calcium loss from estrogen deficiency could be one factor contributing to increased stone formation in postmenopausal women.
The mechanism by which estrogens might regulate calcium reabsorption is incompletely understood. The major part of renal tubular reabsorption of calcium occurs along the proximal tubule and thick ascending limb by a passive paracellular flux. The remaining calcium reabsorption occurs in the distal part of the nephron and is hormonally regulated. This process can be envisaged as a three-step process consisting of facilitated entry across the apical membrane mediated by an epithelial calcium channel (TRPV5), cytosolic diffusion of calcium bound to calcium binding proteins such as calbindin-D 28k , and active extrusion of calcium across the basolateral membrane mediated by PMCA and NCX1. (10) Thus, decreased expression or function of any of these components could impair calcium reabsorption.
The aromatase-deficient mouse is a model of estrogen deficiency caused by inactivation of the gene responsible for biosynthesis of estrogens. (11) In this study, we used the ArKO mouse model to determine whether estrogen deficiency, as opposed to complete gonadal failure of ovariectomy models or surgically induced menopause, is sufficient to alter renal calcium reabsorption and investigate potential underlying mechanisms.
MATERIALS AND METHODS

Animals
The inactivated aromatase gene was maintained on the hybrid 129SvEV/C57Bl6. Female ArKO mice were produced by breeding heterozygotes. In some studies, 10-wkold animals were treated three times per week with 20 g estradiol/mouse, or sesame oil only (placebo) for 3 wk. All procedures were approved by the UT Southwestern IA-CUC.
Analytical studies
Urine was collected from wildtype (WT) and ArKO agematched mice (10-13 wk old) as single spontaneous voids between 1:00 p.m. and 3:00 p.m. or in metabolic cages during an 18-h fast. Urinary calcium was determined by atomic absorption spectroscopy. Urinary creatinine and phosphorous were determined on an automated clinical system, the Roche Mira System. Blood was harvested by closed cardiac puncture at the time of death. Serum 1,25-dihydroxyvitamin D was determined by radioimmunoassay (RIA; Gamma-B 1,25-dihydroxyvitamin D assay; Immunodiagnostic Systems, Fountain Hills, AZ, USA). This assay measures both D 3 and D 2 forms of 1,25-dihydroxyvitamin D. It has a sensitivity of 8 pM, and intra-and interassay CVs of 8% and 14%, respectively. Mouse serum intact PTH(1-84) was measured by enzyme immunoassay (EIA; Intact Mouse PTH; Alpco Diagnostics, Salem, NH, USA). The assay has a sensitivity of 4 pg/ml and intra-and interassay CVs of 3.5% and 8.5%, respectively.
RT and quantitative PCR
Kidneys were powdered under liquid nitrogen (WT, n ‫ס‬ 12; ArKO, n ‫ס‬ 9; ArKO + E, n ‫ס‬ 6; independent samples). The powder was homogenized in TriReagent (Sigma-Aldrich), according to the manufacturer's instructions, to obtain protein, DNA, and RNA in three different phases. Total RNA was treated with DNase to prevent contamination of genomic DNA and finally resuspended in diethylpyrocarbonate-treated milliQ water. Thereafter, 2 g of total RNA was subjected to reverse transcription using Moloney murine leukemia virus RT (Gibco BRL) as described previously. (12) Expression levels of TRPV5, TRPV6, calbindin-D 28k , calbindin-D 9k , plasma membrane calcium ATPase 1b (PMCA-1b), and NCX1 mRNA were analyzed by quantitative real-time PCR, using the ABI Prism 7700 Sequence Detection System (PE Biosystems). With the use of standard curves, the amount of copy numbers of the target genes in each sample was calculated and expressed as a ratio to the hypoxanthine-guanine phosphoribosyl transferase (HPRT) gene. Primers and probes targeting the genes of interest were designed using Primer Express software (Applied Biosystems) and are listed in Table 1 . (13, 14) Expression levels of ER␣ and ER␤ cDNA was synthesized from 2 g total RNA isolated from kidney using multiscribe RT enzyme and random hexamer primers (Superscript II; Invitrogen) in a total vol-ÖZ ET AL. ume of 20 l. Negative controls included RNA without RT. Newly synthesized cDNA (50 ng) was used for real-time PCR reactions. To correct for sample-to-sample variation, mRNA amounts were normalized to cyclophilin as an endogenous reference. Primers for ER␣ and ER␤ were designed using Primer Express software ( Table 2) . Primers that span an exon and Taqman probes were designed to avoid amplification of residual contaminating DNA. For each primer-probe set, serial dilutions of template were conducted to ensure equal efficiency of amplification over a wide range of template concentrations and to ensure that efficiency of amplification was equal to that of cyclophilin. Each real-time reaction included negative and positive controls: cDNA (pooled from four wildtype cycling animals) from mouse uterus and mouse bladder for ER␣ and ER␤, respectively. Real-time PCR reactions were conducted in triplicate using the TaqManTM PCR Reagent Kit. The ABI PRISMTM Sequence Detection System was used to monitor the increase of the reporter fluorescence (Perkin-Elmer, Applied Biosystems). Relative gene expression was calculated using the comparative Ct method as described in the Applied Biosystems User Bulletin 2. Expression levels of klotho and mouse PTH receptor 1 were determined by real-time PCR using Sybr Green and quantitated with the ddC T method. (15) The primer sequences for klotho were based on accession NM 013823. The forward primer sequence was 5Ј-AATTATGTGAATGAGGCTCTGAA-AG-3Ј and the reverse primer sequence was 5Ј-TACGCA-AAGTAGCCACAAAGG-3Ј. The primer sequences for mPTHR1 were based on NM 011199. The forward primer sequence was 5Ј-CAGGGACACTGTGGCAGATC-3Ј, and the reverse primer sequence was 5Ј-CAAAAAATC-CCTGGAAGGAGTT-3Ј. All investigators were blinded to genotypes of the animals during performance of this study.
Western blotting
Renal proteins were obtained from the organic phase of a TriReagent (Sigma) extract of the kidney powder. Protein was harvested from the organic phase by precipitation followed by solubilization in a buffered 1% SDS solution containing protease inhibitors. Protein concentration was determined using a detergent compatible assay (BioRad). The homogenates were subjected to SDS-PAGE on 12.5% polyacrylamide gels or Tris-Tricine gels 9.5% (for calbindin-D 9k only) followed by blotting onto PVDF membrane. The following antibodies were used in this study: mouse monoclonal anti-bovine calbindin-D 28k (Alpha Diagnostic International); rabbit polyclonal anti-calbindin-D 9k (Swant); and rat monoclonal anti-klotho KM2119. (16) Purified porcine intestinal calbindin-D9k was used as a standard for anti-calbindin-D 9k Western blot (Calbiochem). Recombinant rat calbindin-D 28k was used as a standard for anticalbindin-D 28k Western blot (Swant). Recombinant klotho was used as a standard for the anti-klotho antibody. Membranes were probed with primary antibody at the following dilutions or concentration: anti-calbindin-D 28k monoclonal antibody (1:3000), anti-calbindin-D 9k (1:1000), and antiklotho (3 g/ml) overnight at 4°C. Subsequently, the membranes were probed with an appropriate horseradish per-oxidase (HRP)-conjugated secondary antibody, and bands were detected by ECL system (Amersham).
Immunohistochemistry
Kidneys were bisected and embedded in paraffin by standard techniques. Seven-micrometer-thick sections were mounted on glass slides.
Anti-klotho immunohistochemistry: After deparaffinization and rehydration of kidney sections, endogenous peroxidase activity was neutralized by incubating the sections for 30 min with 0.3% H 2 O 2 in methanol. The slides were blocked with normal rabbit serum for 20 min at room temperature. Subsequently, the slides were washed several times. The sections were incubated overnight with a rat monoclonal antibody against recombinant klotho protein. (16) The bound primary antibody was detected using an HRP-conjugated rabbit anti-rat IgG and DAB as substrate (Vector Laboratories). Sections were counterstained with 2% methyl green.
Anti-PTHR1 immunohistochemistry: Deparaffinized and rehydrated sections of mouse kidney underwent antigen retrieval using Vector Laboratories antigen retrieval solution and the manufacturer's suggested procedure. After a 5-min wash in PBS, the slides were treated with 0.1% Triton X-100 in PBS for 20 min, washed, and incubated with 5 mM glycine for 10 min. The slides were further blocked by a 20-min incubation with 3% goat serum (Vector Laboratories). The sections were exposed to a 1:100 dilution of rabbit anti-PTHR1 antibody (Affinity Bioreagents) or to PBS (negative control) overnight at 4°C. Slides were washed for 5 min in PBS and treated with a 1:200 dilution of biotinylated goat anti-rabbit IgG (Vector Laboratories) for 45 min. After a 5-min wash in PBS, slides were further treated with streptavidin-FITC (1:50; Molecular Probes) for 20 min. Slides were rinsed in PBS for 5 min, briefly rinsed in distilled water, shaken, blotted dry, and immediately coverslipped with a xylene-based mounting medium. Sections were examined by confocal microscopy with a Zeiss LSM-510 confocal microscope at a wavelength of 488 nm and ×400 magnification. Human placenta, which does not express PTHR1, was used as a negative control and subjected to the same procedure.
PMCA enzymatic activity
PMCA activity was measured according to a previously published method. (17) Briefly, kidneys were harvested from WT, ArKO, and estradiol-treated ArKO mice after perfusion with cold PBS containing 1 mM EDTA + 1 mM PMSF. The kidneys were minced on ice in a hypotonic buffer containing protease inhibitors. After 15 min, the fragments were homogenized in an equal volume of 0.5 M sucrose + 0.3 M KCl + 1.5 mM EDTA. The homogenate was spun at 5000g to remove unbroken cells and mitochondria. The supernatant was centrifuged at 100,000g for 1 h. The pellet was resuspended in a solution containing 0.25 M sucrose, 0.15 M KCl, 10 mM Tris-HCl, pH 7.5, 2 mM DTT, and 20 M CaCl 2 . Protein concentration was determined using the Bradford method (Bio-Rad). Membrane vesicles (50 g of membrane protein) were added to 140 l of medium con-taining 100 M CaCl 2 and ouabain to inhibit Na-K ATPase, thapsigargin to inhibit SERCA pumps, oligomycin and NaN 3 to inhibit any remaining contaminating mitochondria, and sufficient EGTA to obtain a free calcium concentration of 100 nM. 45 CaCl 2 was added at an activity of 50 Ci/mol of total Ca. The reaction was started by the addition of 6 mM ATP and allowed to proceed for 10 min. Radioactive Ca 2+ accumulation in the membrane preparations was determined by filtration through 0.45-m filters presoaked in 1 mM CaCl 2 to reduce background. The membranes were washed twice with 1 mM CaCl 2 before counting in a ␤counter.
Statistical analysis
Data are expressed as mean ± SE. Comparison of mean values for statistical significance was accomplished by oneway ANOVA. Posthoc analysis was performed by the twotailed Dunnett's test, where the ArKO and estrogentreated ArKO groups were compared with the WT group. Differences were considered significant at the p < 0.05 level.
RESULTS
Hypercalciuria and normophosphaturia in ArKO mice
Urinary calcium, expressed relative to creatinine, was significantly higher in ArKO mice compared with WT mice when examined in spot urine collections (Table 2 ). To better define this hypercalciuria, urine was collected under fasting conditions. In addition, a third group representing estradiol-treated ArKO mice was included. One-way ANOVA disclosed a significant interaction between the three groups (p < 0.001). Posthoc analysis disclosed that ArKO females again showed significant hypercalciuria compared with WT mice. Estrogen-treatment reduced urinary calcium excretion to a value not significantly different from WT. Similar results were also observed when urinary calcium was expressed relative to 100 ml glomerular filtration (Table 1) . Urinary phosphate levels, expressed relative to creatinine, were not different between the groups (WT, 
5Ј-TCGTCATCGGCCGTGAT-3Ј * PCR primers and fluorescent probes (5ЈFAM-3ЈTAMRA) were designed using the computer program Primer Express (Applied Biosystems) and purchased from Applied Biosystems or Biolegio (Malden, The Netherlands 
ArKO mice express lower levels of some proteins involved in transepithelial calcium reabsorption in the DCT that is normalized with estradiol therapy
To determine whether the hypercalciuria was associated with abnormal expression of proteins that mediate transcellular calcium reabsorption, we performed real-time PCR analysis of the expression of TRPV5 and 6, calbindins D 28k and D 9k , PMCA1b, NCX1, and the PTH receptor isoform PTHR1.
For the real-time PCR analysis of expression of each protein analyzed, one-way ANOVA disclosed a significant interaction between the three study groups (p ‫ס‬ 0.029 or less), with the exception of PTHR1 (WT, 0.82 ± 0.08; ArKO, 1.08 ± 0.11; ArKO + E, 0.99 ± 0.11; ANOVA, p ‫ס‬ 0.140). As expected, TRPV5 was more highly expressed than TRPV6 for both genotypes. ArKO mRNA levels were significantly decreased to 50-55% of WT levels for both proteins (Fig. 1) . Calbindin-D 28k mRNA level was significantly decreased in ArKO mice to ∼50% of the WT level. The mRNA level of calbindin-D 9k in ArKO mice was reduced to ∼70% of WT, but the difference was not significant (p ‫ס‬ 0.054, WT versus ArKO). In ArKO kidneys, the mRNA levels of the basolateral membrane proteins, NCX1 and PMCA1b, were decreased. ArKO mRNA level of FIG. 1. Effect of aromatase deficiency and estradiol supplementation on mRNA levels of genes encoding proteins that regulate calcium transport in the kidney. RNA was prepared from whole kidneys and DNase treated to prevent contamination of genomic DNA. cDNA was prepared, and the copy number of the target gene was determined. The data are expressed as the ratio (mean ± SE) of copy number of target gene to the copy number of HPRT or cyclophilin (CPH). WT, wildtype (n ‫ס‬ 12); ArKO, aromatase-deficient mice (n ‫ס‬ 9); ArKO + E, ArKO mice treated with estradiol (n ‫ס‬ 6), 20 g/mouse three times per week for 3 wk. a ArKO vs. WT and b ArKO + E vs. WT.
NCX1 was significantly reduced to ∼55% of WT ( Fig. 1 ). PMCA1b mRNA level was significantly lower in ArKO animals, being ∼68% of WT ( Fig. 1 ). After treatment with estradiol, there was no significant difference in the mRNA levels of TRPV5, calbindin-D 28k , and PMCA1b between treated ArKO mice and WT mice (Fig. 1) . Whereas calbindin-D 28k and D 9k mRNA levels were increased by estradiol therapy such that neither was significantly different from WT, both were significantly higher than untreated ArKO mice (ArKO versus ArKO + E, p < 0.04 by Tukey's posthoc analysis). NCX1 and TRPV6 mRNA levels in kidneys of estradiol treated ArKO mice remained significantly lower than those of the WT mice ( Fig. 1) .
Because estradiol acts through receptors ER␣ and ER␤, mRNA levels of both receptors were assessed. Normalized mRNA level for ER␣ was higher in ArKO kidney than WT, whereas normalized ER␤ level was lower ( Fig. 1) . After estradiol treatment, there was no significant difference between ER␣ mRNA levels of WT and treated ArKO mice ( Fig. 1 ). Expression of ER␤ in ArKO kidney did not significantly change with estradiol therapy (Fig. 1) .
Protein levels of the calbindins in whole kidney extracts were also assessed by Western blot analysis. PTHR1 receptor protein levels and distribution were evaluated by immunohistochemistry. At the protein level, calbindin-D 28k was significantly decreased in ArKO mice (Fig. 2) . Estradiol therapy raised the levels to those of WT. The protein level of calbindin-D 9k in ArKO was not significantly different than that of WT (p ‫ס‬ 0.1). Estradiol therapy raised the mean level of calbindin-D 9k in ArKO mice closer to the WT mean. In agreement with the mRNA data, there was no obvious difference in PTHR1 protein expression, by immunofluorescent histochemistry, between the three groups ( Fig. 3) . Moreover, we did not detect any difference in the cellular distribution of the protein.
Given the resolution of hypercalciuria after estradiol treatment of ArKO mice with a modest increase of PMCA1b in mRNA and no normalization of NCX1, we measured PMCA1 activity in all three experimental groups. The interaction between groups was significant (ANOVA, p ‫ס‬ 0.02). Untreated ArKO mice had lower mean levels of PMCA activity than WT mice, but the difference was not significant (p ‫ס‬ 0.08; Fig. 4 ). On the other hand, ArKO mice treated with estradiol had significantly higher PMCA activity levels compared with WT (p ‫ס‬ 0.04) and untreated ArKO mice (p ‫ס‬ 0.01).
Increased level of klotho protein in ArKO mice
The klotho protein has recently been shown to be a regulator of renal calcium handling through its regulation of TRPV5. Therefore, we studied its expression in the experimental groups. Immunohistochemistry was performed to examine renal klotho expression. The staining was observed in the distal convoluted tubule. Positive staining was both more diffuse and consistently more intense in ArKO kidneys (Fig. 5A ). This increased expression was confirmed by real-time PCR and Western blot analysis (Figs. 5B-5D ). The klotho standard used does not have the transmembrane domain and thus is smaller than the endogenous protein, accounting for the smaller apparent molecular weight on the gels. Estradiol treatment of ArKO mice decreased klotho expression in the kidney at both the mRNA and protein levels (Figs. 5B-5D).
DISCUSSION
In the mammalian kidney, 90% of calcium reabsorption occurs in the proximal tubule and cortical thick ascending limb by paracellular diffusion. The remaining 10% takes place in the distal convoluted tubule through active transcellular transport and is believed to be responsive to calcium-regulating hormones such as PTH and vitamin D. The lack of significant change in vitamin D or PTH levels in the ArKO model suggests that estrogen deficiency is the cause of the hypercalciuria in the ArKO mice. The normal level of urinary phosphorous suggests that the proximal nephron function is intact in ArKO mice. The mechanism(s) by which estrogens may regulate renal calcium reabsorption in the DCT is not completely understood, but decreased expression of proteins involved in renal calcium reabsorption may lead to increased urinary calcium. Indeed, the ArKO mice showed hypercalciuria in both spontaneous voids or 
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with fasting. Although we believe that the observed hypercalciuria in the ArKO female is caused principally by a renal calcium leak in the distal nephron, the current experimental design does not rule out the possibility that an increased renal filtered load of calcium could contribute to the observed hypercalciuria. On the other hand, increased intestinal calcium absorption is not expected to be contributing to an increased filtered load, because serum 1,25dihydroxyvitamin D concentration was observed to be normal in these mice and fasting hypercalciuria was evident.
The decreased expression of TPRV5, calbindin-D 28k , PMCA1b, and NCX1, proteins involved in transcellular reabsorption pathway of calcium, during estrogen deficiency as shown here is consistent with a coordinated regulation. Our findings are reminiscent of the coordinated regulation of the transcellular calcium reabsorption pathway after parathyroidectomy in rats. Similar to these findings during estrogen deficiency, van Abel et al. (18) showed that parathyroidectomized rats have decreased mRNA and protein levels of TRPV5 and calbindin-D 28k , and decreased mRNA levels of NCX1. Although urine calcium was not reported in the study of van Abel et al., serum calcium levels were low, and presumably the animals were hypercalciuric. One difference between the parathyroidectomized rats and the ArKO mice is that PMCA1b mRNA levels were lower in ArKO mice but unchanged in the rats. The cause for this difference between animal models is not known, but clearly, marked deficiency in either PTH or estrogens is sufficient to cause simultaneous decrease of some proteins involved in transcellular calcium transport.
TRPV5 is thought of as a gatekeeper of epithelial calcium uptake (19, 20) and was upregulated at the mRNA level by estradiol treatment of the ArKO mouse. This finding is similar to those of van Abel et al., who showed that estradiol treatment of ovariectomized rats increased renal TRPV5 mRNA and protein expression. (14) In addition, 17␤-estradiol was shown to increase renal mRNA levels of calbindin-D 28K and the basolateral membrane calcium pump PMCA1b. However, when similar studies were performed in male 25-hydroxyvitamin D 3 -1␣-hydroxylaseknockout mice, only TRPV5 expression remained responsive to estrogen. Combined, the two studies suggest a coordinated regulation pattern by estradiol that is independent of vitamin D. In our study, estradiol therapy of ArKO mice also restored TRPV5, calbindin-D 28k , and PMCA1b mRNA levels. Because ArKO mice have normal serum 1,25-dihydroxyvitamin D concentrations, this study supports the conclusion that estrogen regulation of the gatekeeper TRPV5, calbindin-D 28k , and PMCA1b in the kidney occurs in a coordinated fashion and can occur independently of vitamin D.
The TRPV6 calcium channel is also expressed in the kid- ney but at much lower levels compared with TRPV5. Weber et al. (21) studied the response of renal TRPV6 in ovariectomized mice with and without estradiol treatment at doses similar to ours. Expression was higher in the ovariectomized mice. After estradiol administration, the expression level decreased to a point between that of the sham and ovariectomized groups. Unfortunately, the authors did not perform statistical analysis to determine the significance of the increase but concluded that expression of TRPV6 in the kidney is independent of estradiol levels. In contrast, we observed significantly decreased TRPV6 expression in ArKO mice that was unchanged with estradiol therapy. Taken together, the results suggest that ovarian factors other than estradiol maybe involved in regulation of renal TRPV6 and that TRPV6 is not important for normalizing transepithelial calcium transport after an estradiol challenge. Although TRPV5 and TRPV6 are involved in calcium uptake at the apical surface, PMCA1b and NCX1 are responsible for transport of calcium into the blood at the basolateral surface. In the ArKO mice, estradiol therapy increased the mRNA levels of PMCA1b to a point not statistically different from WT levels, although mean levels were still lower. Moreover, this treatment increased PMCA1b activity significantly above that in WT and untreated ArKO mice. This observation is reminiscent of in vitro studies showing estradiol can enhance the activity of PMCA1b in a renal tubule cell line without changes in expression levels. (22) On the other hand, the same dose failed to increase NCX1 expression. These observations, together with normalization of urine calcium level in treated ArKO mice, suggested that, whereas both NCX1 and PMCA1b are important in calcium extrusion under basal conditions, it is PMCA1b that is responsible for extruding calcium in response to an estrogen challenge. However, we can not exclude that NCX1 is an estrogen regulated protein because increased expression of NCX1 mRNA has been reported by van Abel et al. (14) after estradiol therapy at doses of 250 g/d and higher, a dose that exceeded ours by 4-fold. Nevertheless, the observed increased enzymatic activity and modest changes in PMCA mRNA level after estradiol treatment seem sufficient for normal calcium efflux.
Recent reports of the glucuronidase klotho regulating TRPV5 activity (23) prompted us to compare the levels of klotho expression in WT and ArKO kidneys. The ArKO mice had increased levels of the klotho protein. Clues to the function of the klotho protein were originally discovered as a result of random insertional mutagenesis in mice resulting in many phenotypes seen in aging. (24) To our knowledge, this is the first report that estrogens regulate renal klotho expression. The increased expression of klotho in aromatase deficiency may be a compensatory physiological response to increased urinary calcium to compensate for decreased expression of the TRPV5 gatekeeper by prolonging its presence and activity on the surface membrane. (23) The fact that mRNA levels decreased after estradiol therapy suggests that estradiol regulates klotho expression at the transcriptional level. In addition to the results shown in this report, estradiol regulates klotho expression in the MDBK and MDCK kidney cell lines (A Hajibeigi and OK Öz, unpublished results, 2007) . In contrast to our findings of suppression of klotho expression by estradiol, others have shown upregulation of klotho expression after a single injection of vitamin D. (25) Although klotho-deficient mice have been shown to have defective PTH-induced luminal calcium reabsorption, (26) to our knowledge, the regulation of klotho protein expression in the kidney by PTH in the intact mouse has not been reported. Thus, klotho regulation by calcitropic hormones needs further study but is likely to be different for each hormone.
Estrogens act through two receptors, namely ER␣ and ER␤. Estrogen receptors have been found in the mammalian kidney. (27) A prior study in ␣ERKO AF-1−/− mice reported mRNA levels of renal calcium transport proteins were also decreased. (28) The ER␣ splice variant expressed by these mice lacks the AF-1 domain but retains the ability to signal through classical genomic mechanisms. To our knowledge, there are no published studies that show changes in expression of calcium transport proteins in the kidneys of ER␤ knockout mice. Therefore, it seems that ER␣ is the mediator of estrogen action at the kidney, and regulation of the calcium reabsorption pathway by estrogens may not involve classical genomic signaling. One advantage to the ArKO model is the ability to study effects on molecular expression after estradiol treatment, which allowed us to determine the estrogen responsiveness of urinary calcium excretion and protein expression abnormalities. The facts that both ArKO and ␣ERKO AF-1−/− mice show decreased levels of the same calcium transport proteins and ␣ERKO AF-1−/− female mice have elevated estra-FIG. 4. Effect of aromatase deficiency and estradiol supplementation on PMCA activity. Membrane vesicles (50 g of membrane protein) prepared from whole kidneys were added to a buffer containing CaCl 2 and inhibitors of Na-K ATPase, SERCA pumps, and mitochondrial calcium transport. 45 CaCl 2 was added at an activity of 50 Ci/mol of total Ca. The PMCA reaction was initiated by the addition of 6 mM ATP, allowed to proceed for 10 min, and terminated by filtration through 0.45-m filters. WT, wildtype; ArKO, aromatase-deficient mice; ArKO + E, ArKO mice treated with estradiol, 20 g/mouse three times per week for 3 wk. a ArKO + E vs. WT and b ArKO + E vs. ArKO. diol levels, whereas ArKO mice have undetectable estradiol levels, establish that ligand-dependent pathways acting through ER␣ are important regulators of renal calcium transport in vivo.
In summary, estrogen deficiency, produced by aromatase inactivation, is sufficient to cause renal calcium loss. The calcium loss is independent of changes in vitamin D and PTH. The decreased calcium reabsorption is associated with coordinated decreased expression of the genes for some renal calcium transport proteins including TRPV5 and 6, calbindin-D 28k , NCX1, and PMCA1b; however, normocalciuria after estradiol therapy is associated with a coordinated increase in expression only for TRPV5, calbindin-D 28k , and PMCA1b. This implies that, whereas TPRV6 and NCX1 maybe involved in basal calcium transport in the kidney, they are not responsible for estradiol-mediated increases in renal calcium reabsorption. Taken together with previous work by other groups, we suggest that estrogen regulates renal calcium reabsorption at the transcriptional level through ER␣ acting to regulate these genes in a coordinated ligand dependent fashion but the regulation may not be solely through classical estrogen response elements. In addition, estradiol may regulate the process through nontranscriptional based regulatory mechanisms such as klotho regulating activity of TRPV5 and estradiol regulation of PMCA enzymatic activity. The study findings may provide an explanation for the increased risk of nephrolithiasis and the observed increased incidence in females at the menopause. Patients with congenital aromatase deficiency or those being treated with aromatase inhibitors for breast cancer may also be at increased risk for hypercalciuria and nephrolithiasis. The findings also suggest attention to urinary calcium levels in patients being treated with aromatase inhibitors for delaying growth plate closure. Finally, deficiency of calcitropic hormones seems to have common and unique effects on the expression of renal calcium transport proteins. (29) Understanding the molecular basis for differences in expression of calcium transport proteins after parathyroidectomy, aromatase inactivation, or in vitamin D insufficiency may be helpful in understanding the complex physiological regulation of renal calcium reabsorption in the distal convoluted tubule leading to improved health care for patients at risk for nephrolithiasis as well as bone loss.
ACKNOWLEDGMENTS
The authors thank Alexia Thomas for colony management and genotyping animals, Jan Koska and Kathy Rodgers for analytical studies on urine, Alan Stewart for serum analysis, Patrick Keller for performing quantitative realtime RT-PCR of the ERs, Angie Bookout for designing the klotho primers, Jocelyn Chafouleas for manuscript preparation, and Virginia Barnett, Glenn Katz, and Dorothy Smith for graphics support. This work was supported in part by a grant from the seed account of the Center for Mineral Metabolism and Clinical Research at UT Southwestern Medical Center, in part by NIH HD01463, P01DK20543, and unrestricted funds from the endowment of the Effie and Wofford Cain Distinguished Chair in Diagnostic Imaging. 
